Artemisinin‐based combination therapy (ACT) is one strategy recommended to increase
cure rates in malaria and to contain resistance to Plasmodium falciparum. In the Maheba …

Summary In the Maheba Refugee Settlement, in the clinics supported by Médecins Sans
Frontières, all children aged up to 5 years with a confirmed diagnosis of uncomplicated …

Faced with the problem of resistance to chloroquine and sulfadoxine-pyrimethamine, the
Ministry of Public Health of Burundi decided to study the efficacy of two artemisinin-based …

Artemisinin-containing antimalarial combination therapies are recommended to confront
drug-resistant Plasmodium falciparum malaria. Among the questions surrounding whether …

We undertook a trial of artesunate+ amodiaquine (AS+ AQ) and artesunate+ sulphadoxine–
pyrimethamine (AS+ SP) in 180 children of age 6–59 months with uncomplicated malaria in …

The efficacy of any artemisinin-based combination therapy (ACT) depends on adherence to
the treatment regimen (Nosten and Brasseur, 2002). In the present study, adherence to AL …

Background One year after the adoption of artesunate-amodiaquine (AS/AQ) as first-line
therapy for the treatment of uncomplicated malaria, this study was designed to assess the …

Background Following the development of resistance to anti-malarial mono-therapies,
malaria endemic countries in Africa now use artemisinin-based combination therapy (ACT) …

Background The use of artemisinin-based combination therapy (ACT) at the community level
has been advocated as a means to increase access to effective antimalarial medicines by …

Background There are no data on the long term use of an artemisinin combination treatment
in moderate or high transmission areas of Africa. Methods and findings Artesunate plus …